CytomX Therapeutics, Inc.
CTMX
$0.9284
-$0.1616-14.83%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 5,700.88% | 235.84% | 126.25% | 123.40% | 99.43% |
| Total Depreciation and Amortization | -18.71% | -19.85% | -22.17% | -15.97% | -10.97% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 34.49% | -23.37% | -62.17% | -71.26% | -70.92% |
| Change in Net Operating Assets | -102.23% | -214.22% | -370.40% | -1,725.77% | -103.92% |
| Cash from Operations | -53.89% | -148.94% | -68.01% | -52.06% | 49.42% |
| Capital Expenditure | 63.10% | 34.39% | 57.99% | 13.78% | 51.72% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 166.75% | 255.52% | 283.72% | 189.63% | -249.83% |
| Cash from Investing | 166.17% | 252.90% | 271.39% | 185.74% | -253.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,240.82% | 988.17% | 988.17% | 14.66% | -13.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -75.12% | -81.72% | 6,840.04% | 4,643.21% | 4,565.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.89% | 121.25% | 80.09% | 81.17% | -1,385.51% |